TrialThe Journal of infectious diseases2015

Safety and Immunogenicity of Cell Culture-Derived A/H3N2 Variant Influenza Vaccines: A Phase I Randomized, Observer-Blind, Dose-Ranging Study.

Casey Johnson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.